Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway

Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Immunology

All About (NK Cell-Mediated) Death in Two Acts and an Unexpected Encore: Initiation, Execution and Activation of Adaptive Immunity

Ariel Ramirez-Labrada et al.

Summary: In this article, the available experimental evidence on how NK cells kill target cells is reviewed and discussed, with a special focus on the different cell death modalities that have been found to be activated during NK cell-mediated cytotoxicity, including apoptosis and more inflammatory pathways like necroptosis and pyroptosis. Based on this new evidence, NK cell-induced cell death is proposed as a new regulatory mechanism linking innate immune response with the activation of tumor adaptive T cell responses.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy

Jessica Wenthe et al.

Summary: LOAd703, an immunostimulatory oncolytic adenovirus, shows potential in enhancing anti-lymphoma immune responses and improving CAR T-cell therapy efficacy in B-cell lymphoma models. LOAd703-infected lymphoma cells can stimulate CAR T-cell functionality resulting in enhanced cytokine release, degranulation marker expression, and reduced inhibitory receptor expression, leading to increased lymphoma cell killing. Additionally, LOAd703-infected lymphoma cells upregulate secretion of chemokines essential for immune cell homing, facilitating enhanced CAR T-cell migration.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Review Cell Biology

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development

Ali Bashiri Dezfouli et al.

Summary: In recent years, cell-based immunotherapies using Chimeric Antigen Receptors (CARs) have shown promise in cancer treatment, with CD19 CAR-engineered T cells being most commonly used for hematological malignancies. However, challenges in clinical applications include side effects like cytokine release syndrome, neurological symptoms, and off-target effects, necessitating the development of safer and more potent technologies. Natural Killer (NK) cells have emerged as a promising alternative, being capable of CAR engineering and exhibiting specialized lytic mechanisms against virally infected and cancer cells.

CELLS (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Navigating CAR-T cells through the solid-tumour microenvironment

Andrew J. Hou et al.

Summary: CAR-T cells have limited efficacy in treating solid tumors, but various engineering strategies can overcome the obstacles posed by the tumor microenvironment, producing next-generation T cells with enhanced specificity and sustained effector function.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Review Cell & Tissue Engineering

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

Faroogh Marofi et al.

Summary: CAR-NK cells are safer and more efficient than CAR-T cells in treating tumors, especially hematological malignancies. NK cells can be effectively engineered to express CARs with substantial cytotoxic activity against both hematological and solid tumors.

STEM CELL RESEARCH & THERAPY (2021)

添加到收藏夹

Article Genetics & Heredity

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

Deepak Vangala et al.

Summary: By testing in vivo selection of anti-EGFR SR tumors in CRC PDX models, researchers have revealed the molecular details of developing secondary resistance mechanisms in CRC, suggesting that anti-EGFR tolerant cells via transcriptional reprogramming may be a common cause. Successful treatment of secondary resistant xenograft tumors was achieved using tailored targeted therapies.

GENOME MEDICINE (2021)

添加到收藏夹

Article Oncology

Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma

Dashnamoorthy Ravi et al.

LEUKEMIA (2020)

添加到收藏夹

Article Medicine, General & Internal

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Enli Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction

Nathan Singh et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer

Christian Sordo-Bahamonde et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

添加到收藏夹

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Medicine, General & Internal

CAR-NK cells: A promising cellular immunotherapy for cancer

Guozhu Xie et al.

EBIOMEDICINE (2020)

添加到收藏夹

Article Oncology

Altered T-Lymphocyte Biology Following High-Dose Melphalan and Autologous Stem Cell Transplantation With Implications for Adoptive T-Cell Therapy

Thomas Mika et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy

Liwei Jiang et al.

CELL (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

Mohamed-Reda Benmebarek et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Review Cell Biology

Mechanisms of natural killer cell-mediated cellular cytotoxicity

Isabel Prager et al.

JOURNAL OF LEUKOCYTE BIOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Immunology

NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing

Isabel Prager et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2019)

添加到收藏夹

Article Cell Biology

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

Katrin Mestermann et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Meeting Abstract Hematology

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Ryan N. Rys et al.

BLOOD (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

Jianguang Zhang et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

添加到收藏夹

Review Oncology

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities

Sattva S. Neelapu et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Hematology

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy

Marie de Charette et al.

HAEMATOLOGICA (2018)

添加到收藏夹

Review Hematology

Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy

Marie de Charette et al.

HAEMATOLOGICA (2018)

添加到收藏夹

Article Oncology

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions

Lee K. Hong et al.

CANCER IMMUNOLOGY RESEARCH (2018)

添加到收藏夹

Article Immunology

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

Congcong Zhang et al.

FRONTIERS IN IMMUNOLOGY (2017)

添加到收藏夹

Article Cell & Tissue Engineering

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma

Sarah Oelsner et al.

CYTOTHERAPY (2017)

添加到收藏夹

Article Oncology

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

Congcong Zhang et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

添加到收藏夹

Article Oncology

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

Congcong Zhang et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)

添加到收藏夹

Article Cell Biology

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies

Annette Romanski et al.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)

添加到收藏夹

Article Medicine, Research & Experimental

CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients

Cameron J. Turtle et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹

Article Multidisciplinary Sciences

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

Jianfeng Han et al.

SCIENTIFIC REPORTS (2015)

添加到收藏夹

Article Oncology

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

Michael Hudecek et al.

CANCER IMMUNOLOGY RESEARCH (2015)

添加到收藏夹

Article Hematology

Classification of human natural killer cells based on migration behavior and cytotoxic response

Bruno Vanherberghen et al.

BLOOD (2013)

添加到收藏夹

Article Oncology

MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL

Alexander Baraniskin et al.

CARCINOGENESIS (2012)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy

Tolga Sutlu et al.

HUMAN GENE THERAPY (2012)

添加到收藏夹

Article Oncology

Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor

James N. Kochenderfer et al.

JOURNAL OF IMMUNOTHERAPY (2009)

添加到收藏夹

Review Immunology

Functions of natural killer cells

Eric Vivier et al.

NATURE IMMUNOLOGY (2008)

添加到收藏夹

Article Immunology

Bystander macrophage apoptosis after Mycobacterium tuberculosis H37Ra infection

Deirdre M. Kelly et al.

INFECTION AND IMMUNITY (2008)

添加到收藏夹

Article Biochemical Research Methods

FL-CTL assay: Fluorolysometric determination of cell-mediated cytotoxicity using green fluorescent protein and red fluorescent protein expressing target cells

K Chen et al.

JOURNAL OF IMMUNOLOGICAL METHODS (2005)

添加到收藏夹

Article Immunology

Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway

AL Snow et al.

JOURNAL OF IMMUNOLOGY (2001)

添加到收藏夹

Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway

相关参考文献

导出引文

分享论文